ABOUT US

WADE'S ARMY is a non-profit organization inviting everyone to join the front lines of the fight against neuroblastoma. For the past 10 years we have fought with muscle and kindness, bringing people together to raise money directly for children and parents affected by this childhood cancer, while also supporting research initiatives and hospitals fighting to find a cure. Our Army of supporters has made it possible for us to fund 5 clinical research trials, supported 27 families and committed more than $625,000 to clinical research to find a cure for this terrible disease.

Neuroblastoma is a very rare type of cancerous tumor that almost always affects children. It accounts for 50% of all cancer in infants and is the leading cause of cancer death in children under the age of 5. There are about 750 cases of the disease each year in the United States alone and yet ~15% of all childhood cancer deaths can be attributed to neuroblastoma.

AWARENESS IS THE FIRST STEP TOWARDS A CURE

Join our family in the fight against neuroblastoma

Cancer is a word everyone knows, and a word no one wants to hear. Wade's Army was founded by the Welbourn and DeBruin families to recruit others to use their Power for good and bring the fight to this pediatric cancer.

Play video

USING OUR POWER FOR GOOD TO FIGHT NEUROBLASTOMA

WADE'S ARMY NUTRITION EDUCATION PROGRAM

We are excited to announce the launch of the WADE'S ARMY Teaching Kitchen located within the UNC Medical Center Hosptial. Our teaching kitchen will provide nutrient dense meals for cancer patients and their families on the best ways to use food as medicine.

TITAN

We have joined forces with siz parent led non-profits in a landmark pediatric oncology reseearch initiative. Children with high-risk neuroblastoma across Europe and North America will be treated together for the first time, following the award of $1.4M to fund a new transatlantic clincial trial led by Dr. Yael Mosse of Children's Hospital of Philadelphia and Dr. Dominique Valteau-Couanet of Gustave Roussy in Paris, investigating the ALK inhivitor lorlatinib in the treatment of children with newly diagnosed high-rish neuroblastoma.

PHASE 1 CLINICAL TRIAL: CAR-T THERAPY

In the phase 1 clinical trial, Dr. George Hucks, Assistant Professor of Pediatrics Division of Pediatric Hematology/Oncology Bone Marrow Transplant is assessing the safety of the CAR-T therapy at the UNC Lineberger Comprehensive Cancer Center.

THE CHILDREN'S HOSPITAL OF PHILADELPHIA

In partnership with 9 other investors, including Pfizer and University of Southern California, WADE'S ARMY has jointly funded the Phase 2 Study of Lorlatinib (PF-06463922),, an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients with ALK-Driven Relapsed or Refractory Neuroblastoma.

Stay connected with our newsletter